Shareholders’ meeting 2024
Category: Press release
Availability of Transgene’s 2023 Universal Registration Document
URD 2023
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
TG4050 AACR 2024
Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
appointment Lucie Larguier et Christelle Schwoerer
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
2023 financial results and business update
Transgene Announces Upcoming Investor Meetings
upcoming investor meetings
Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024
TG4050 AACR 2024
Transgene, Nec, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
Transgene Nec and BostonGene expand collaboration
Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer
financial calendar 2024
Transgene Announces Financial Calendar for 2024
financial calendar 2024
